hotspot -WSS

hotspot

author：comprehensive 2025-09-30 00:50:27 - browse：5995

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Zyn nicotine pouches become unlikely player in latest culture war

WSS

Syphilis numbers in the United States reach record heights

Mass General, Mayo Clinic look to monetize custom

Medicare drug price lawsuits could be good politics for Biden

Head of FDA's diagnostics center, who led through Covid, retires

How generative AI ratchets up security threats for health systems

FDA endorses new sterilization method for medical devices

hotspot

hotspot

focus

Tori Bowie and the unacceptable rates of Black maternal death

TikTok, Instagram influencers need more rules for drug ads

Jerome Adams on the need for new antivirals for Covid

Why you shouldn’t ask, “What country has the best health care?”

Tori Bowie and the unacceptable rates of Black maternal death

White House pharmacy plagued with problems, investigation finds

In Memoriam: Notable people who died in 2023

Future doctors need a strong humanities education

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Maisha Meds is a PBM, but don't call it that

hotspot

Dog Aging Project founders on what lies ahead after losing funding

Printout prescription drug information shouldn’t go digital

Mass General, Mayo Clinic look to monetize custom

FDA sets aggressive timeline for overhauling inspection procedures

Inaction leaves children at risk from dangerous chemotherapy drug

The inclusion problem at the heart of rehabilitation research

leisure time

entertainment

Wikipedia

hotspot